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Abstract 
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal 
complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of 
reduced dose are alternative treatment strategies. We report a case of severe ILD in a 
non-small cell lung cancer patient treated with gefitinib. She experienced partial 
response with restarted low-dose EGFR-TKI erlotinib and corticosteroid treatment. 
 
Introduction 
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as 
gefitinib and erlotinib, have been shown to have significant antitumor activity in non-
small cell lung cancer (NSCLC) patients with EGFR mutations. Although the common 
side effects of EGFR-TKIs (including skin rash, diarrhea, asthenia and anorexia) are mild 
and controllable, interstitial lung disease (ILD) remains a rare but always fatal 
complication. The disease will relapse after EGFR-TKI suspension which is mandatory to 
rescue the patients who contracted the ILD. We report a case of severe ILD in a NSCLC 
patient treated with gefitinib. She experienced partial response with restarted low-dose 
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A 41-year-old woman who complained of non-productive cough and breathlessness was diagnosed 
with lung adenocarcinoma stage IV (T2aN3M1a) in November 2009. Chest computed tomography (CT) 
revealed a 3.0 × 2.6-cm mass in the left lower lobe and left pleural effusion (fig. 1a). EGFR mutation 
status was not evaluated. Because first-line chemotherapy with paclitaxel plus cisplatin cannot be 
tolerated for grade 3 gastrointestinal side effects, she received gefitinib 250 mg/day as second-line 
treatment. Only 7 days after the start of gefitinib, the symptoms disappeared. However after 20 days’ 
treatment of gefitinib, the patient reported high fever and severe respiratory distress on effort. Despite 
high-flow supplemental oxygen delivered via nasal cannula, hypoxemia developed with a PaO2 of less 
than 45 mm Hg. A chest CT revealed bilateral pulmonary infiltrates, patchy airspace consolidation, and 
air bronchograms despite decreased size of the primary tumor (fig. 1b). The diagnosis of EGFR-TKI-
induced interstitial lung disease was made, and gefitinib therapy was stopped. Mechanical ventilation 
and corticosteroid treatment (120 mg/day of intravenous methylpredonisolone) were started 
immediately. The patient experienced improvement and weaned from the ventilator after 8 days of 
treatment. Repeated CT scan showed complete resolution of infiltrates. The corticosteroid was tapered 
over 1 month. 
In June 2010, the patient developed progressive disease after 4 cycles of docetaxel-cisplatin 
chemotherapy (fig. 1c). From July 2010, erlotinib (75 mg/day) was prescribed with oral prednisolone (20 
mg/day). She achieved a partial response after 1 month’s treatment of erlotinib (fig. 1d). The 
prednisolone was withdrawn after 3 months without recurrence of EGFR-TKI-induced ILD. She is still 
alive 1 year after the restart of EGFR-TKI therapy. 
Discussion 
The worldwide incidence of ILD is about 1% in both gefitinib- or erlotinib-treated 
patients; ILD was reported to have a prevalence of 3.5% and mortality of 1.6% in gefitinib-
treated patients in Japan [1]. For the patients who had partial or complete response to 
gefitinib and experienced gefitinib-induced ILD, obligatory suspension of EGFR-TKI 
treatment will cause progression of disease. After recovery from ILD, most of the patients 
received chemotherapy, which is not as effective as EGFR-TKI. Although a case with 
recurrent gefitinib-induced ILD was reported [2], a reduced dose of gefitinib might 
induce a response without recurrent gefitinib-induced ILD [3]. Several cases of NSCLC 
successfully rechallenged with erlotinib after developing gefitinib-induced ILD were also 
described [4, 5]. We add another case report which shows that a reduced dose of erlotinib 
in combination with steroid therapy achieved partial response in a patient recovered from 
gefitinib-induced ILD. So a reduced dose of erlotinib seems to be a potential therapeutic 
option for the treatment of NSCLC patients who develop gefitinib-induced ILD, although 
it is required to pay attention to the possibility of the development of recurrent ILD. The 
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Fig. 1. a CT scan shows a mass in the left lower lobe at the diagnosis of lung adenocarcinoma. b Chest 
CT after gefitinib treatment revealed patchy airspace consolidation and air bronchograms despite 
decreased size of the primary tumor. c Chest CT revealed progress of disease after 4 cycles of 
chemotherapy. d After one month of treatment of erlotinib, a partial response was seen. 
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